Therapeutics And Clinical Risk Management

雜志介紹

Therapeutics And Clinical Risk Management雜志介紹

《Therapeutics And Clinical Risk Management》是一本以English為主的開放獲取國際優秀期刊，中文名稱治療學和臨床風險管理，本刊主要出版、報道醫學-HEALTH CARE SCIENCES & SERVICES領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為2.3，最新CiteScore 指數為5.3。

本刊近期中國學者發表的論文主要有：

• LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis

  Author: Zuo, Tao; Jiang, Ping; Fu, Jun; Zhang, Yongjian

• Research on the Influence of the Allogeneic Bone Graft in Postoperative Recovery After MOWHTO: A Retrospective Study

  Author: Zhong, Rui; Yu, Gang; Wang, Yingming; Fang, Chao; Lu, Shuai; Liu, Zhilin; Gao, Jingyu; Yan, Chengyuan; Zhao, Qichun

• Identifying the Risk Factors for Postoperative Sore Throat After Endotracheal Intubation for Oral and Maxillofacial Surgery

  Author: Zheng, Zhou-peng; Tang, Su-lin; Fu, Shao-lan; Wang, Qian; Jin, Li-wei; Zhang, Yan-li; Huang, Rong-rong

• Thoracic Paravertebral Block Decreased Body Temperature in Thoracoscopic Lobectomy Patients: A Randomized Controlled Trial

  Author: Yan, Yanhong; Geng, Jiao; Cui, Xu; Lei, Guiyu; Wu, Lili; Wang, Guyan

英文介紹

Therapeutics And Clinical Risk Management雜志英文介紹

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.

The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.

As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.

The journal does not accept study protocols, animal-based or cell line-based studies.